Independent Supplement Reporting · Updated September 2026

The Heart Health Review

Heart Health

Blood Pressure

Cholesterol

Research

Supplement Investigation

5 Reasons This Smelly Japanese Food Could Be a Game-Changer for Black Heart Health

Heart disease kills more Black Americans than any other group. The standard advice has not closed the gap in 50 years. A 1,000-year-old enzyme from Japan targets the one thing everything else misses.

By the HHR Editorial Team · September 5, 2026 · 5 min read

If you are a Black adult in America, the numbers are not in your favor. Fifty-six percent of Black adults have high blood pressure — the highest rate of any group in the country. Black Americans develop hypertension earlier and at more severe levels. Stroke rates in Black adults under 55 are nearly double the national average.

And the advice most people get — eat better, exercise more, take your statin — has not closed the gap. Not in ten years. Not in fifty.

This is not a willpower problem. It is a targeting problem. The standard approach targets the numbers on the blood test. But the actual killer — the plaque buildup inside the artery wall — is something most medications and supplements were never designed to remove.

In Japan, they have been eating a food every morning that does something none of those can do. It is called natto — fermented soybeans — and the enzyme it produces, nattokinase, directly breaks down the fibrin mesh that holds arterial plaque together.

Here are five reasons this matters — especially for Black Americans.

Title

The Standard Approach Keeps Failing — Because It Targets the Wrong Thing

Statins lower cholesterol production. Fish oil works on triglycerides. Garlic nudges blood pressure. Each one manages a number on the chart. Some of those numbers improve.

But arterial plaque — the actual buildup — forms when the artery wall gets damaged from chronic inflammation, high blood pressure, or oxidative stress. The body sends a protein called fibrin to patch the site. Cholesterol gets trapped inside that fibrin mesh. Over time, it hardens. The artery narrows.

Lowering cholesterol does not break down what is already deposited inside the artery. This is why someone can eat clean, exercise, take three medications — and their imaging still shows buildup. The pipe is still clogged. They are just running less through it.

For Black Americans — who develop higher blood pressure earlier, sustain more arterial damage over time, and accumulate deposits at a faster rate — this gap between managing the numbers and addressing the buildup is the difference between a routine checkup and a 2 AM ambulance ride.

Japan Has One-Fifth the Heart Disease Deaths — With Worse Risk Factors Than Ours

Japan has the longest life expectancy of any G7 country — 85.2 years. Their heart disease death rate is one-fifth that of the United States.

The paradox: Japanese men have comparable cholesterol to American men. They smoke at higher rates. Their blood pressure is as high or higher. By every standard risk factor, they should have worse outcomes. They don't.

When Japanese men move to the United States, their heart disease rates go up. Same genes. Different diet. Different outcomes. The protection is not genetic — it is dietary.

The variable every study keeps isolating: natto. The fermented soybean dish eaten at breakfast every morning across the country. The enzyme it contains — nattokinase — enters the bloodstream and breaks apart the fibrin strands holding plaque together, releasing the trapped cholesterol so the body can clear it naturally.

Over 120,000 People Studied Across Decades — This Is Not a Small Study

Most supplement research involves small studies with modest results. Nattokinase is different.

The Research

29,079 adults over 16 years — highest natto intake group had 25% lower cardiovascular death. No other soy food produced this effect.

92,915 adults over 14.8 years — natto was linked to lower cardiovascular death in both men and women. Tofu, soy milk, and edamame were not.

1,062 adults over 12 months — the group taking the full clinical dose saw plaque reduced up to 36%. The low-dose group saw nothing.

The pattern repeats across every major study: only the fermented version works. Only at the right dose.

The Dose Determines Everything — and Most Products Get It Wrong

The largest clinical study found that 10,800 FU per day reduced plaque up to 36% and artery wall thickness by roughly 22%. The group taking 3,600 FU? No significant changes. Another trial gave 2,000 FU per day for three years — zero measurable effect.

Most nattokinase supplements provide 2,000 to 4,000 FU per serving. That is the dose range proven to produce no result — one-fifth to two-fifths of what actually worked.

This is the single most important variable in the category. The enzyme is real. The mechanism is proven. But if the bottle does not contain enough of it, nothing happens.

Clearing the Buildup Is Only Step One — You Need All Three

Breaking down plaque without addressing the inflammation that caused it means new deposits form behind what was just cleared. And if the artery wall itself stays weakened, it remains vulnerable to re-injury.

For Black Americans — who face higher rates of chronic inflammation and sustained arterial damage — addressing all three stages is not optional. It is the whole point.

A complete approach requires three stages: clear the buildup, stop the inflammation that rebuilds it, and protect the arteries underneath.

Henoura Nattokinase

10,000 FU per serving · 7 ingredients · All three stages

Stage 1

Clear the Buildup

Nattokinase (10,000 FU) + Bromelain

Stage 2

Stop the Inflammation

Turmeric + Aged Garlic Extract

Stage 3

Protect the Arteries

CoQ10 + Grape Seed + Pine Bark

60-Day Money-Back Guarantee

Third-Party Tested

Made in USA

See Full Ingredient Panel

Real customers. Real results.

Title

The buildup does not wait. And the standard advice is not keeping up.

10,000 FU nattokinase. Seven supporting ingredients. Three stages. One daily serving.

Shop Henoura

60-day money-back guarantee · Third-party tested · Made in USA

Disclosure: This article contains affiliate links. The Heart Health Review may earn a commission on purchases made through links in this article at no additional cost to you. Editorial recommendations are based on review of published clinical research and label inspection.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before starting any new supplement, especially if you are taking blood thinners, are scheduled for surgery, or are pregnant or nursing.

Health disparity statistics sourced from the American Heart Association, CDC, and published epidemiological research. Japanese cardiovascular data sourced from Circulation (Iso, 2008), INTERLIPID Study (Ueshima et al., 2003), GBD Study 2021. Natto population studies: Nagata et al., AJCN, 2017; Katagiri et al., BMJ, 2020; Fujita et al., Clinical Nutrition ESPEN, 2025. Nattokinase clinical research: Chen et al., Frontiers in Cardiovascular Medicine, 2022; Hodis et al., NAPS Trial, 2021.

10,000 FU Nattokinase + Three-Stage System

SHOP NOW